Dabigatran for catastrophic antiphospholipid syndrome.
Por:
Sarrate E, Olive A, Morales-Indiano C, Santos-Gómez M, Orna E, Monreal M and Sorigue M
Publicada:
1 oct 2019
Resumen:
: Vitamin K antagonists (VKA) remain the treatment of choice for catastrophic antiphosphilipid syndrome (CAPS). However, when VKAs do not work for a specific patient, direct oral anticoagulants (DOAC) may be a valid therapeutic alternative. We present a patient with a psychiatric disorder and CAPS who was noncompliant to VKA and low-molecular-weight heparin. He was started on dabigatran and has remained thrombosis-free for 8 years. Due to CAPS he has developed progressive renal failure but dabigatran levels were within the expected range. In conclusion, this case report provides anecdotic evidence that dabigatran may be of use in patients with high-risk APS in whom VKA are not an option.
Filiaciones:
Sarrate E:
Hematology Laboratory. ICO-Badalona, Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona
Olive A:
Rheumatology Service, Hospital Universitari Germans Trias i Pujol
Morales-Indiano C:
Clinical Laboratory ICS-Metropolitana Nord, Core-Hematology Department, Hospital Germans Trias i Pujol
Santos-Gómez M:
Hematology Laboratory. ICO-Badalona, Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona
Orna E:
Hematology Laboratory. ICO-Badalona, Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona
Monreal M:
Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol de Badalona, Barcelona, Spain
Sorigue M:
Hematology Laboratory. ICO-Badalona, Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona
|